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ABSTRACT 
Background: Stroke prevention in anticoagulation-naïve patients with atrial fibrillation 
undergoing cardioversion has not been systematically studied. 
Objective:  To determine outcomes in anticoagulation-naïve patients (defined as those receiving 
an anticoagulant for <48 hours during the index episode of AF) scheduled for cardioversion. 
Methods: This is a randomized, prospective, open-label, real world study comparing apixaban to 
heparin plus warfarin.  Early image-guided cardioversion is encouraged.  For apixaban, the usual 
dose is 5 mg BID with a dose reduction to 2.5 mg BID if two of the following are present: age> 
80 years, weight < 60 kg, or serum creatinine > 1.5 mg/dL.  If cardioversion is immediate, a 
single starting dose of 10 mg (or 5 mg if the dose is down-titrated) of apixaban is administered.  
Cardioversion may be attempted up to 90 days after randomization.  Patients are followed for 30 
days following cardioversion or 90 days post-randomization if cardioversion is not performed 
within that timeframe.  Outcomes are stroke, systemic embolization, major bleeds, clinically 
relevant non-major bleeding, and death, all adjudication–blinded. 
Statistics: The warfarin-naive cohort from the ARISTOTLE study
 
was considered the closest 
data set to the patients being recruited into this study.  The predicted incidence of stroke, 
systemic embolism, and major bleeding within 30 days after randomization was approximately 
0.75%.  To adequately power for a non–inferiority trial, approximately 48,000 subjects would be 
needed, a number in excess of feasibility.  The figure of 1,500 patients was considered clinically 
meaningful and achievable. 
Clinical context: This first prospective cardioversion study of a novel anticoagulant in 
anticoagulation-naïve patients should influence clinical practice. 
Trial registration number NCT02100228 
Abstract: 257 words 
Keywords: Atrial fibrillation, apixaban, anticoagulation, cardioversion, prospective 
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INTRODUCTION 
Non-valvular atrial fibrillation (NVAF) is a modern epidemic affecting 1 in 4 adults aged 60 
years and older.
1  
Electrical or pharmacological cardioversion or both together are standard 
practice for restoring sinus rhythm in selected patients with persistent AF.
2
  The risk of peri - 
procedural thromboembolism may exceed 5% when anticoagulation is inadequate.
3,4
 Therapeutic 
anticoagulation with a vitamin K antagonist (VKA) reduces the risk to less than 1%.
5-7
  Current 
practice guidelines recommend anticoagulation for at least 3 weeks before and at least 4 weeks 
after cardioversion for patients with AF lasting more than 48 hours or when the duration is 
uncertain.
2,8,9
  Secondary post hoc analyses of the Randomized Evaluation of Long-Term 
Anticoagulation Therapy (RE-LY trial)
7
, the Apixaban for Reduction in Stroke and Other 
Thromboembolic Events in Atrial Fibrillation (ARISTOTLE trial),
10
 and the Rivaroxaban Once 
Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of 
Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF trial)
11
 suggest that the non-VKA 
oral anticoagulants (NOACs) may be a reasonable alternative to heparin and warfarin for patients 
with NVAF  undergoing cardioversion and that event rates are very low (Table 1).  The major 
limitation of these post hoc analyses, however, is the prolonged period of anticoagulation 
preceding the cardioversion.  The need for more immediate cardioversion frequently arises in 
patients presenting with newly identified atrial fibrillation.  The eXplore the efficacy and safety 
of once-daily oral riVaroxaban for prEvention of caRdiovascular events in Patients with 
nonvalvular aTrial fibrillation (X-VeRT) trial
12
 was the first prospective trial of a NOAC in the 
setting of cardioversion and found rivaroxaban, an oral factor Xa inhibitor, comparable to VKA 
in patients with NVAF undergoing cardioversion within 5 days or after 3 weeks and up to a 
maximum of 8 weeks of anticoagulation, once again with very low event rates ( 0.5 and 0.6 % 
for efficacy and safety for rivaroxaban and 1.0 and 0.8 % for usual therapy , both not 
significantly different).  No studies have specifically evaluated a NOAC in a population of 
patients who are anticoagulation-naïve who are undergoing cardioversion.  EMANATE will 
uniquely address cardioversion in this population. 
Apixaban 
Apixaban is an orally active, reversible, direct inhibitor of human coagulation Factor Xa (FXa) 
developed jointly by Bristol-Myers Squibb (BMS) and Pfizer as an anti-thrombotic agent, now 
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licensed globally for the prevention of stroke and systemic embolization in patient with NVAF 
and for treatment and prevention of venous and thromboembolic disease.
13
 
OBJECTIVES 
The goal of this study is to assess clinical outcomes in patients randomized to apixaban against 
conventional anticoagulant care (parenteral heparin and/or a VKA) in patients with recently 
detected AF considered for cardioversion.  The protocol encourages an image-guided approach 
(transesophageal echocardiography or computerized tomography), or anticoagulation for a 
minimum of 3 weeks prior to cardioversion.
2,8
  To avoid confounding by prior treatment, the 
study focuses on patients who are anticoagulation-naïve, excluding patients receiving any 
anticoagulant for >48 hours during the index episode of AF.  Another aim of the study is to 
define predictors of a successful outcome at 30 days after cardioversion. 
DESIGN 
This is a randomized, active-controlled, open-label study of approximately 1,500 patients 
randomized 1:1 to apixaban or usual care (parenteral heparin and/or oral anticoagulation with 
VKAs (goal INR 2.0-3.0, excluding other NOACs; Figure 1).  Anticoagulation is administered 
from randomization until 30 days following cardioversion.  If cardioversion is not performed, 
anticoagulation will be administered for a maximum of 90 days.  Clinical data including 
cardioversion details, efficacy and safety outcomes, length of in-hospital stay, and information 
regarding image guidance are collected.  The apixaban dose is 5 mg BID, with a dose reduction 
to 2.5 mg BID if at least two of the following exist: age > 80 years, weight < 60 kg, or serum 
creatinine >1.5 mg/dL.  Five doses of apixaban will be administered prior to cardioversion to 
achieve steady state blood levels.  If an immediate cardioversion is planned, a single 10 mg dose 
(or 5 mg if the dose is down-titrated) is administered at least 2 hours prior to cardioversion to 
more rapidly bring exposure up to steady state.  Investigators will use their local label for dose 
adjustment guidance for subjects with renal impairment. 
Subjects randomized to apixaban will transition from their pre-existing anticoagulant (oral and/ 
or parenteral) of less than 48 hours as follows.  For subjects receiving a VKA, apixaban is started 
when the INR is below 2.0.  For all NOACs, discontinue the drug and begin apixaban at the next 
scheduled dose, but no earlier than 12 hours after the previous oral anticoagulant administration.  
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For low molecular weight heparin, apixaban should be started at the time of the next scheduled 
dose and no earlier than 12 hours after the previous parenteral anticoagulation administration.  
For intravenous infusion of unfractionated heparin, apixaban should be started immediately to 2 
hours after IV UFH has been stopped. 
For subjects randomized to usual therapy, stop NOAC and start warfarin immediately, and start 
heparin at the time of the next dose of the novel agent and continue until the INR is above 2.  In 
general patients will be managed according the local clinician’s usual practice and in a manner 
consistent with the design of the study. 
Statistical Considerations 
There was no precedent for evaluating anticoagulation-naïve patients in the setting of 
cardioversion.  The warfarin-naive cohort from the ARISTOTLE study
14 
was considered the 
closest data set to the patients being recruited into this study.  The incidence of stroke and 
systemic embolism within 30 days after randomization was 0.3% (1 stroke or systemic embolism 
on apixaban and 3 events on usual care).  The incidence for major bleeding was 0.45 (2 events on 
apixaban and 5 events on usual care).  To adequately power for non–inferiority, 480 endpoints 
would be needed (similar to ARISTOTLE 
15
).  In this study, follow up is limited to 30 days 
following cardioversion or 90 days’ post-randomization.  An estimated event rate of 
approximately 1% would require 48,000 subjects, a number far in excess of practicality.  The 
figure of 1,500 patients was considered clinically meaningful and achievable.  Kaplan-Meier 
curves of the time to first adjudicated stroke or systemic embolism, first major bleeding event, 
and composite of first major bleed and clinically relevant non-major bleed as well as all-cause 
death will be generated. 
Executive Committee 
The Executive Committee (EC) comprises five academic experts, four sponsor representatives 
(non-voting) and a biostatistician.  The EC takes sole responsibility for the study design, trial 
management, data analysis, and writing of the manuscript.  The EC reviews recommendations 
from the Data Monitoring Committee and oversees the presentation and publication of the 
results.  The EC is aided by a Clinical Research Organization and by designated national leaders 
in both cardiology and emergency medicine in the participating countries.  This trial is sponsored 
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by Bristol-Myers Squibb and Pfizer.  The authors acknowledge the editorial assistance of Ms. 
Paulette Trent. 
Data Monitoring Committee 
An independent Data Monitoring Committee (DMC) is responsible for monitoring the safety of 
subjects in the study and recommending alterations of the study to the EC and the sponsor.  The 
sponsor forwards decisions, which may include aggregate analyses of endpoint events and safety 
data that are not endpoints, to regulatory authorities as appropriate. 
STUDY PROCEDURES (Figure 2) 
Screening  
The investigator or designee at each participating clinical site obtains written informed consent 
from each participant, as well as contact and demographic information, relevant medical history, 
CHA2DS2VASc score, and evaluates clinical laboratory results.  The patient must meet inclusion 
and exclusion criteria, including electrocardiographic confirmation of heart rhythm (Table 2).  
This table additionally compares the inclusion and exclusion criteria from the first completed 
trial of rivaroxaban (X-VeRT)
16
 and a second ongoing trial of edoxaban (ENSURE-AF)
17 
 that, 
like EMANATE, prospectively evaluate novel anticoagulants in the setting of cardioversion. 
Randomization 
Randomization uses a centralized interactive voice-response system (IVRS).  Study medication 
is dispensed in accordance with local policies and procedures, with accounting recorded on case 
report forms (CRFs).  Patients can be randomized and cardioverted on the same day, combining 
Visits 1 and 2. 
Cardioversion 
The following details are recorded for each cardioversion attempted: time and date attempted, 
whether pharmacological, electrical, both pharmacological and electrical, or spontaneous, local 
investigator interpretation of image guidance, type of image guidance, number, date, and time of 
cardioversion attempts, rhythm status after cardioversion, and adverse events. 
Compliance 
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Compliance with apixaban is based on pill counts at the time of cardioversion and at the end of 
the study.  For patients randomized to usual care, compliance is assessed by INR monitoring. 
Image Guidance  
In the event TEE or CT imaging identifies atrial thrombus, cardioversion is deferred for at least 3 
weeks.  Assigned anticoagulation continues and imaging is repeated to confirm resolution of 
thrombus prior to cardioversion.    We encourage investigators to continue assigned medication 
in patients identified with thrombus and repeat imaging studies after 3 weeks. 
 Management of Bleeding 
Anticoagulation is interrupted in the event of clinically significant bleeding and managed 
according to local practice, which may include such measures as surgical hemostasis, volume 
repletion, transfusion of blood products and for patients in the conventional therapy arm, 
administration of protamine and supplemental Vitamin K fresh frozen plasma as deemed 
appropriate by the treating physician.  An antidote to apixaban is in development but is not yet 
approved.
18
 
 Treatment Transitions 
At the end of the study or upon early withdrawal from the study, the patient’s subsequent 
management and treatment are conducted by the treating physician according to usual practice.  
When an alternative anticoagulation strategy is necessary, the protocol recommends the 
transition procedures contained in the apixaban package insert.
13 
Subject Withdrawal 
Subjects may withdraw from the study at any time upon request, at the discretion of the 
investigator or sponsor for safety or behavioral reasons, or due to the inability of the subject to 
comply with the required schedule of visits or procedures.  Subjects withdrawn from the study 
are subsequently managed according to conventional practice.  Every effort will be made to 
ensure follow-up for outcomes relevant to the trial objectives. 
ASSESSMENT 
Clinical outcomes 
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Clinical outcomes are assessed by local investigators to determine whether a protocol-specified 
outcome had occurred.  Events are recorded and reviewed by independent adjudicators blinded to 
treatment allocation.  The clinical outcomes are the occurrence of acute stroke, systemic 
embolism, all-cause death, major bleeding, and clinically relevant non-major bleeding. 
Acute Stroke 
Stroke is defined as a focal neurological deficit of sudden onset, lasting at least 24 hours, not due 
to a readily identifiable non-vascular cause.  Strokes are classified as primary ischemic, 
hemorrhagic, infarction with hemorrhagic conversion, or of unknown type if no imaging is 
available in accordance with definitions established by the American College of Cardiology 
(ACC).
19
  A diagnosis of primary hemorrhagic stroke requires documentation by imaging of 
hemorrhage in the cerebral parenchyma or in the subdural or subarachnoid space or evidence of 
hemorrhage obtained by lumbar puncture, neurosurgery or identified at autopsy.  Non-
hemorrhagic stroke is a focal neurological deficit resulting from thrombosis or embolism evident 
at 24 hours.  Infarction with hemorrhagic conversion requires absence of hemorrhage on initial 
scan but evidence of hemorrhage on subsequent scan.  Stroke of unknown type is designated 
when brain imaging is not available. 
Extracranial Systemic Embolism 
Systemic embolism is defined by a clinical presentation consistent with acute loss of blood 
supply to an anatomical site supplied by a single artery, supported by evidence from 
angiography, surgical specimens, autopsy, or other objective testing. 
Major Bleeding 
Clinically overt bleeding is defined as visible bleeding, or signs or symptoms suggestive of 
bleeding with confirmatory imaging that detects the presence of blood (e.g., ultrasound, CT, or 
magnetic resonance).  The definition of major bleeding adapted from the International Society on 
Thrombosis and Hemostasis (ISTH)
20
 requires clinically overt bleeding accompanied by one or 
more of the following: a decrease in hemoglobin (Hgb) of >2 g/dL; transfusion of >2 units of 
packed red blood cells; bleeding that occurs in at least one of the following critical sites: 
intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is 
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not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, 
retroperitoneal; or bleeding that is fatal. 
Clinically Relevant Non-Major Bleeding 
The definition of clinically overt bleeding in the EMANATE protocol is adapted from the ISTH 
guidelines.
21
  Clinically relevant non-major bleeding is overt bleeding that compromises 
hemodynamics, leads to hospitalization, produces subcutaneous hematoma >25 cm
2
, or 100 cm
2
 
if traumatic, intramuscular hematoma documented by ultrasonography, epistaxis lasting >5 
minutes or repetitive (i.e., two or more episodes of bleeding within 24 hours or leads to 
intervention (e.g., packing or electrocoagulation); gingival bleeding occurring spontaneously 
(i.e., unrelated to eating or tooth brushing) or lasting >5 minutes; spontaneous macroscopic 
hematuria lasting >24 hours after instrumentation (e.g., catheter placement or surgery); 
macroscopic gastrointestinal hemorrhage, including at >1 episode of melena or hematemesis, if 
clinically apparent and hemoptysis outside the context of pulmonary embolism; or any other 
bleeding considered to have clinical consequences such as medical intervention, unscheduled 
contact (visit or telephone call) with a physician, temporary interruption of study drug, or 
associated with pain or impaired activities of daily life. 
Length of Hospital Stay 
The date and time of each hospital admission and discharge will be recorded. 
ADVERSE EVENTS 
An adverse event (AE) is defined as any untoward medical occurrence or worsening of a pre-
existing medical condition in a subject administered an anticoagulant during the course of the 
study. 
Serious Adverse Events 
Serious adverse events (SAEs) are untoward medical occurrence that are life-threatening or fatal, 
require inpatient hospitalization or prolong an existing hospitalization, result in persistent or 
significant disability or incapacity, congenital anomaly or birth defect, require intervention to 
prevent permanent impairment or damage, or based on medical judgment are important medical 
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events that place a subject in jeopardy and require medical or surgical intervention to prevent one of the 
aforementioned outcomes. 
Discussion 
The novelty of this trial is the exclusive enrollment of anticoagulant-naïve patients with recently 
detected AF with a focus on enrolling those patients amenable to early cardioversion.  Also 
unique, if an immediate cardioversion is planned, is the administration of a loading dose of 10 
mg (or 5 mg, if the dose is down-titrated) of apixaban at least 2 hours prior to cardioversion.  
This is done to more rapidly achieve a steady state of anticoagulation.  For this reason, potential 
participants are being actively identified in hospital Emergency Departments. Image-guided 
cardioversion with TEEs or CT scans is of special interest.  Thus the Assessment of 
Cardioversion Use in Transesophageal Echocardiography(ACUTE) study
6
, a multicenter, 
randomized trial comparing a TEE-guided strategy of abbreviated therapeutic anticoagulation 
with intravenous unfractionated heparin started 24 hours before cardioversion against 
conventional warfarin (INR 2.0-3.0) for at least 3 weeks before cardioversion, provided 
important background information.  The investigators enrolled 1,222 patients with AF of >2 
days’ duration and found no significant difference between the two strategies in the rate of 
thromboembolic events over an 8-week period.  The rate of hemorrhagic events was lower in the 
TEE-guided group (18 events [2.9%] vs 33 events [5.5%], p=0.03).  The TEE group had a 
shorter time to cardioversion (mean ± SD, 3.0±5.6 vs. 30.6±10.6 days).  The authors concluded 
that the strategy of TEE-guided treatment was a safe and effective alternative to the conventional 
treatment strategy.
6
 
Additional data relevant to cardioversion derive from a post-hoc subgroup analysis of the 
ARISTOTLE trial, in which 540 subjects underwent 743 cardioversions and were followed for 
30 days following cardioversion.  No stroke or systemic embolic events occurred in patients 
randomized to apixaban or warfarin.  One major bleeding event and two deaths were observed in 
each group.
10
  All subjects undergoing cardioversion in that trial had been chronically 
anticoagulated prior to cardioversion so there was no information on the safety of apixaban in 
subjects newly presenting with AF or in those patients naïve to anticoagulation in whom early 
cardioversion is indicated.  The EMANATE trial is designed to fill this important information 
gap. 
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The first and largest post-hoc analysis of cardioversion was in the RE-LY trial, which found 
similarly low event rates in groups treated with warfarin or either of two doses of dabigatran, 150 
mg BID or 110 mg BID.
7
  The analysis provided grounds for optimism regarding the potential 
use of a NOAC in this setting (Table 1).  Subsequently, secondary analysis of the ROCKET-AF 
trial described a similar experience with rivaroxaban in a smaller number of patients insofar as 
event rates were low (Table 1).
11
  The ENGAGE-AF trial of edoxaban also included patients 
undergoing cardioversion, but the data are not currently available. 
The only prospective trial to specifically address cardioversion was the X-VERT trial, which 
tested rivaroxaban against usual therapy.
12
  Site investigators decided whether to randomize 
subjects to early (1-5 days after randomization) or delayed cardioversion (between 21-56 days 
after randomization).  Event rates were low in both arms, with a non-significant trend favoring 
rivaroxaban.  Another ongoing prospective trial, ENSURE-AF, is evaluating edoxaban against 
usual care in patients with AF undergoing cardioversion.
17 
Limitations 
EMANATE is an ongoing open-label trial.  There is precedent for conducting open-label 
anticoagulation trials with blinded adjudication.
12, 17, 23-25
  The outcomes of these completed trials 
are very similar to those of completed double-blind trials,
10,11,25,26 
thus confirming the validity of 
this type of trial design. 
We also describe the difficulty of conducting a statistically valid non-inferiority trial in the 
setting of cardioversion because of the very large sample size required because of low event rates 
reported in all the recent cardioversion trials evaluating novel agents.  This limitation was 
recognized in the design of the comparable X-VeRT and ENSURE-AF trials.  We did consider a 
cohort study using apixaban alone with comparison to historic controls; however, the unique 
feature of EMANATE is the anticoagulation-naïve population for which a historical control 
group would not be available.  There is evidence that apixaban is being used in the setting of 
cardioversion in certain sites without direct evidence to support this approach.  We do believe 
that this study fills an important data gap and that the results of this study should bear 
importantly upon future clinical practice. 
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Figure 1.  EMANATE study design  
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Figure 2.  Subject flow 
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  Table 1. Clinical outcome event rates within 30 days post-cardioversion in RE-LY
7
, ARISTOTLE
10
, and ROCKET-AF
11
 studies 
 
 RE-LY             
dabigatran 
150 mg 
RE-LY               
dabigatran 
110 mg 
RE-LY  
warfarin 
ARISTOTLE 
apixaban 
ARISTOTLE 
warfarin 
ROCKET-AF* 
rivaroxaban 
ROCKET-AF* 
warfarin 
Stroke
†
 or 
systemic 
embolism 
0.30 0.77 0.60 0 0 1.88 1.86 
Major bleeding 
‡
 0.60 1.70 0.60 0.30 0.20 18.75 13.04 
Death
§
 n/a n/a n/a 0.6 0.5 1.88 3.73 
 
* ROCKET-AF combined event rates for cardioversion and ablation procedure 
†
 Both ischemic and hemorrhagic strokes 
‡ 
ROCKET-AF combined major and non-major clinically relevant bleeding 
§ 
RE-LY did not report death rates within 30 days of cardioversion 
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Table 2. Inclusion criteria for EMANATE, X-VeRT, and ENSURE-AF 
EMANATE X-VeRT ENSURE-AF 
Subjects with non-valvular atrial 
fibrillation (as documented by 
electrocardiogram (ECG) at Visit 1) 
indicated for cardioversion and initiation 
of anticoagulation in accordance with the 
approved local label. Subjects presenting 
with atrial flutter with no evidence of 
atrial fibrillation are not eligible for 
enrolment. 
Hemodynamically stable nonvalvular AF 
> 48 hours or of unknown duration 
Ongoing nonvalvular AF lasting for at 
least 48 hours but ≤ 12 months 
Age ≥18 years (Age ≥ 19 years for Korea 
only and Age ≥ 20 years for Japan only) 
Men or women aged > 18 y Male or female subjects older than the 
minimum legal adult age (country 
specific) 
Written informed consent Written informed consent Signed informed consent form 
The subject is willing to provide contact 
details for at least one alternate person for 
study staff to contact regarding their 
whereabouts, should the subject be lost-
to-follow-up over the course of the study. 
(Subject to IRB/IEC approval) 
Scheduled for cardioversion (electrical or 
pharmacological) of nonvalvular AF 
Ongoing nonvalvular AF at the time of 
randomization should be confirmed by 
any electrical tracing (e.g., routine 12-lead 
electrocardiogram [ECG], Holter monitor 
rhythm strip, intracardiac electrogram, or 
pacemaker) prior to randomization. 
Female subjects of childbearing potential 
must agree to use a highly effective 
method of contraception throughout the 
study and for at least 28 days after the last 
dose of assigned treatment.   
Women of childbearing potential and men 
must agree to use adequate contraception 
when sexually active 
Duration and proof of AF during the 
previous 12 months can be confirmed by 
any electrical tracing or a recording in the 
subject’s medical records (e.g., medical 
chart, hospital discharge summary) 
Subjects who are willing and able to  Symptomatic subjects with no known 
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comply with scheduled visits, treatment 
plan, and other study procedures. 
history of AF and no prior electrical 
tracing or recording of/about the cardiac 
rhythm available for the past 12 months 
may be randomized into the study if there 
is reasonable belief that the current 
episode of AF lasts for at least 48 hours 
and no longer than 12 months 
  
  
  
  Subject is planned for electrical 
cardioversion 
  Subjects with AF following a cardiac 
surgical procedure (including catheter 
ablation) will be allowed into the study 
providing that they meet all the other 
inclusion criteria AND the time from the 
surgery to randomization is no less than 
30 days. 
  The Investigator will be responsible for 
assessment of risks relevant to the 
cardioversion procedure in such subjects. 
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Table 2. Exclusion criteria for EMANATE, X-VeRT, and ENSURE-AF 
EMANATE X-VeRT ENSURE-AF 
Having taken more than 48 hours of an 
anticoagulant (oral and/or parenteral) 
immediately prior to randomization. 
Severe, disabling stroke (modified 
Rankin score of 4-5, inclusive) within 3 
months or any stroke within 14 days 
before the randomization visit 
AF considered to be of a transient or 
reversible nature (such as in myocarditis, 
post-surgery [unless the duration of AF post-
cardiac surgery is N 30 days, refer to 
inclusion criterion #4], ionic disturbances, 
thyrotoxicosis, pneumonia, severe anemia 
etc.) 
Contraindications to apixaban or usual 
care (eg, VKA) in accordance with the 
approved local label 
Transient ischemic attack within 3 days 
before randomization 
Subjects with a history of left atrial 
appendage (LAA) closure (either by surgery 
or by a procedure) 
Severe hemodynamically compromised 
subjects requiring emergent cardioversion 
Acute thromboembolic events or 
thrombosis (venous/arterial) within the 
last 14 days before randomization 
Subjects with acute myocardial infarction, 
stroke, acute coronary syndrome, or 
percutaneous coronary intervention within 
the previous 30 days or receiving DAPT 
regardless of when the event has occurred 
Hemodynamically significant mitral 
stenosis, mechanical or biological 
prosthetic valve or valve repair. 
Acute MI within the last 14 days before 
randomization 
Subjects with moderate or severe mitral 
stenosis, mitral valve rheumatic disease, 
unresected atrial myxoma, or a mechanical 
heart valve (subjects with bioprosthetic heart 
valves and/or valve repair can be included) 
and/or other conditions, such as pulmonary 
embolism, considered to be a formal 
indication for conventional anticoagulation 
-However subjects with AF and valvular 
heart diseases such as mitral valve prolapse, 
mitral valve regurgitation, and aortic valve 
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disease are allowed in the study 
Conditions other than atrial fibrillation 
that require chronic anticoagulation (eg, a 
prosthetic heart valve). 
Cardiac-related criteria (known 
presence of left atrial/LAA thrombus 
before study inclusion, known presence 
of atrial myxoma, known left 
ventricular or aortic thrombus, valvular 
heart disease [either hemodynamically 
significant mitral valve stenosis or 
prosthetic heart valve]) 
Known presence of a thrombus in LAA, left 
atrium, left ventricle, aorta or intracardial 
mass 
Simultaneous treatment with both aspirin 
and a thienopyridine (eg, clopidogrel, 
ticlopidine, prasugrel) or simultaneous 
treatment with both aspirin and ticagrelor 
Active bleeding or high risk of 
bleeding contraindicating anticoagulant 
therapy 
Signs of bleeding or conditions associated 
with high risk of bleeding including major 
surgeries or biopsies in the last 10 days 
Pregnant females; breastfeeding females; 
females of childbearing potential who are 
unwilling or unable to use a highly 
effective method of contraception as 
outlined in this protocol for the duration 
of the study and for at least 28 days after 
last dose of investigational product. 
Concomitant drug therapies: 
-Indications for anticoagulant therapy 
for a condition other than AF (e.g., 
VTE) 
-Chronic ASA therapy>100 mg daily 
or dual antiplatelet therapy 
-Concomitant use of strong inhibitors 
of both CYP3A4 and P-gp (ie, all HIV 
protease inhibitors and the following 
azole antimycotic agents: ketoconazole, 
itraconazole, voriconazole, 
posaconazole, if used systemically) 
Subjects with any contraindication to 
anticoagulant agents 
Participation in other studies involving 
investigational drug(s) (Phases 1-4) within 
Concomitant conditions: Subjects with conditions associated with 
high risk of bleeding such as a past history of 
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30 days before the current study begins 
and/or during study participation.  Note: 
Subjects cannot be randomized into this 
study more than once. 
-Childbearing potential without proper 
contraceptive measures, pregnancy, or 
breastfeeding 
-Hypersensitivity to investigational 
treatment or comparator treatment 
-Calculated  CrCl <30 mL/min 
-Hepatic disease associated with 
coagulopathy leading to a clinically 
relevant bleeding risk 
-Severe conditions leading to life 
expectancy of < 6 months 
-Planned invasive procedure with 
potential for uncontrolled bleeding 
(including major surgery or cardiac 
catheterization) 
-Inability to take oral medication 
-Ongoing drug addiction or drug abuse 
intracranial (spontaneous or traumatic), 
spontaneous intraocular, spinal, 
retroperitoneal or intra-articular bleeding; 
overt gastrointestinal bleeding or active ulcer 
within the previous year; recent severe 
trauma, major surgery, or deep organ biopsy 
within the previous 10 days; active infective 
endocarditis; uncontrolled hypertension 
(blood pressure [BP] above 170/100 mmHg); 
or hemorrhagic disorder including known or 
suspected hereditary or acquired bleeding or 
coagulation disorder 
Severe acute or chronic medical or 
psychiatric condition or laboratory 
abnormality that may increase the risk 
associated with study participation or 
investigational product administration or 
may interfere with the interpretation of 
study results and, in the judgment of the 
investigator, would make the subject 
inappropriate for entry into this study. 
Any other contraindication listed in the 
local labeling for the comparator 
treatment or experimental treatment 
Subjects receiving dual antiplatelet therapy 
(eg, aspirin plus thienopyridine such as 
clopidogrel, prasugrel or ticagrelor) or 
anticipated to receive such therapy 
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Investigational site staff members directly 
involved in the conduct of the trial and 
their family members, site staff members 
otherwise supervised by the Investigator, 
or subjects who are BMS/Pfizer 
employees directly involved in the 
conduct of the trial 
Participation in a study with an 
investigational drug or medical device 
within 30 days before randomization 
Subjects receiving prohibited concomitant 
medications (fibrinolytics, non-study 
anticoagulants other than those used as a 
bridge to/from study drug), chronic oral or 
parenteral Non-Aspirin/Non-Steroidal Anti-
Inflammatory Drugs (NSAID) use for ≥ 4 
days/week 
 Previous randomization in this study Subjects receiving chronic cyclosporine 
therapy 
 Inability to comply with the study 
procedures 
Subjects with active liver disease or 
persistent (confirmed by repeat assessments 
at least a week apart) elevation of liver 
enzymes/bilirubin: Alanine transaminase or 
aspartate transaminase ≥3× upper limit of 
normal (ULN); Total bilirubin (TBL) ≥ 2× 
ULN (however, subjects whose elevated 
TBL is due to known Gilbert’s syndrome 
may be included in the study); 
  Subjects with renal failure (end stage renal 
disease, calculated CrCl b15 mL/min); 
  Subjects with hemoglobin b10 g/dL or 
platelet count b100,000 cells/mcL or white 
blood cell count b3000 cells/mcL; 
  Subjects with pre-planned invasive 
procedures (other than routine endoscopy) or 
surgeries in which bleeding is anticipated 
during the study period; 
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  Subjects who received any investigational 
drug or device within 30 days prior to 
randomization, or plan to receive such 
investigational therapy during the study 
period; 
  Women of childbearing potential without 
proper contraceptive measures, and women 
who are pregnant or breast feeding 
 Note: Childbearing potential without 
proper contraceptive measures (ie, a method 
of contraception with a failure rate <1% 
during the course of the study (including the 
observational period). These methods of 
contraception according to the note for 
guidance on non-clinical safety studies for 
the conduct of human trials for 
pharmaceuticals (CPMP/ICH/286/95, 
modification) include consistent and correct 
use of hormone containing implants and 
injectables, combined oral contraceptives, 
hormone containing intrauterine devices, 
surgical sterilization, sexual abstinence, and 
vasectomy for the male partner); 
  Subjects with the following diagnoses or 
situations: 
-Active cancer undergoing chemotherapy, 
radiation or major surgery within in the next 
3 months; 
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-Significant active concurrent medical illness 
or infection; Life expectancy b6 months; 
  Subjects who are unlikely to comply with the 
protocol (eg, uncooperative attitude, inability 
to return for subsequent visits, and/or 
otherwise considered by the Investigator to 
be unlikely to complete the study 
  Subjects with a known drug or alcohol 
dependence within the past 12 months as 
judged by the Investigator 
  Subjects with any condition that, in the 
opinion of the Investigator, would place the 
subject at increased risk of harm if he/she 
participated in the study 
 
